Chemomab Therapeutics Ltd.
CMMBHealthcare|Biotechnology|IL
$1.32
+0.07 (+5.60%)
DCF Value
$1.56
Tangible Book / Share
$1.09
Cash / Share
$0.84
Financials
Financial Snapshot
Market Cap
$8.9M
Enterprise Value
$2.9M
Revenue (TTM)
$0.00
Net Income (TTM)
-$7.6M
Cash & Investments
$6.7M
Net Cash
$6.7M
Free Cash Flow (TTM)
-$11.2M
Operating CF (TTM)
-$11.2M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$6.7M
Quarterly Burn
$2.8M
Monthly Burn
$934.9K
Est. Runway
~2.4 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $4.6M | $1.5M | $7.5M | $17.6M | $11.7M | $61.2M | $39.9M | $19.8M | $14.3M | $10.4M | $6.7M | |
| Operating Cash Flow | -$3.7M | -$8.6M | -$14.2M | -$16.5M | -$12.8M | -$12.4M | -$20.3M | -$23.6M | -$15.5M | -$11.2M | -$11.2M | |
| Free Cash Flow | -$3.8M | -$8.6M | -$14.4M | -$16.6M | -$12.8M | -$12.6M | -$20.4M | -$23.6M | -$15.5M | -$11.2M | -$11.2M | |
| Capital Expenditure | -$76.1K | -$34.3K | -$212.3K | -$95.3K | -$34.2K | -$239.2K | -$67.7K | -$3.0K | $4.96 | -$3.0K | -$3.0K | |
| Financing Cash Flow | $6.1M | $5.3M | $20.6M | $26.7M | $299.1K | $61.1M | -$804.8K | $3.5M | $9.9M | $7.2M | $7.2M |
R&D Spending
R&D (TTM)
$4.1M
R&D Intensity
—
R&D Growth vs Prior
-28.9%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $2.3M | $6.2M | $7.5M | $13.3M | $3.8M | $6.3M | $17.0M | $18.4M | $11.3M | $5.8M | $4.1M | |
| SG&A | $2.3M | $3.1M | $5.5M | $6.0M | $7.1M | $6.0M | $11.6M | $7.1M | $3.4M | $3.7M | $3.8M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $40.6K | $51.0K | $66.0K | $281.9K | $80.6K | $34.0K | $57.8K | $66.8K | $0.00 | $0.00 | $0.00 | |
| Gross Profit | -$40.6K | -$51.0K | -$65.8K | -$282.0K | -$80.6K | -$34.0K | -$57.8K | -$66.8K | $0.00 | $0.00 | $0.00 | |
| R&D | $2.3M | $6.2M | $7.5M | $13.3M | $3.8M | $6.3M | $17.0M | $18.4M | $11.3M | $5.8M | $4.1M | |
| SG&A | $2.3M | $3.1M | $5.5M | $6.0M | $7.1M | $6.0M | $11.6M | $7.1M | $3.4M | $3.7M | $3.8M | |
| Operating Income | -$4.6M | -$9.4M | -$13.0M | -$19.6M | -$11.0M | -$12.4M | -$28.5M | -$25.5M | -$14.7M | -$9.6M | -$8.0M | |
| Interest Expense | $0.00 | $5.0K | $0.00 | $9.0K | $6.0K | $111.1K | $353.0K | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$4.6M | -$9.6M | -$5.9M | -$27.2M | -$11.7M | -$12.5M | -$28.2M | -$24.2M | -$13.9M | -$9.0M | -$7.6M | |
| Net Income | -$4.7M | -$9.8M | -$13.8M | -$27.2M | -$11.7M | -$12.5M | -$27.6M | -$24.2M | -$13.9M | -$9.0M | -$7.6M | |
| EPS (Diluted) | -69.00 | -875.98 | -87.09 | -63.20 | -504.20 | -4.80 | -9.68 | -8.22 | -68.80 | -1.42 | -1.02 | |
| EBITDA | -$4.6M | -$9.5M | -$13.4M | -$26.9M | -$11.0M | -$12.3M | -$28.5M | -$25.4M | -$14.7M | -$9.5M | -$7.9M | |
| Shares Out. (M) | 0.07 | 0.01 | 0.16 | 0.43 | 0.02 | 2.59 | 2.84 | 2.94 | 0.20 | 6.38 | 8.00 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.6M | $1.5M | $7.5M | $17.6M | $11.7M | $15.2M | $13.5M | $9.3M | $6.1M | $7.6M | $6.0M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $24.0K | $46.0M | $26.4M | $10.5M | $8.2M | $2.8M | $688.0K | |
| Total Current Assets | $4.9M | $1.6M | $10.9M | $18.2M | $11.8M | $62.7M | $41.7M | $20.9M | $16.0M | $13.4M | $10.0M | |
| Total Assets | $5.6M | $2.1M | $12.8M | $19.8M | $12.5M | $64.4M | $43.1M | $22.2M | $17.0M | $13.8M | $10.2M | |
| Total Current Liabilities | $2.4M | $2.7M | $2.7M | $4.1M | $1.3M | $2.6M | $6.7M | $4.8M | $3.2M | $1.5M | $1.6M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $2.4M | $2.7M | $3.0M | $4.8M | $1.7M | $2.9M | $6.8M | $5.2M | $3.4M | $1.5M | $1.6M | |
| Stockholders' Equity | $3.3M | -$609.0K | $9.8M | $12.4M | $10.8M | $61.5M | $36.2M | $17.0M | $13.5M | $12.3M | $8.7M | |
| Retained Earnings | -$52.7M | -$62.9M | -$78.3M | -$17.7M | -$23.7M | -$36.2M | -$63.8M | -$88.7M | -$102.6M | -$111.6M | -$115.6M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.7M | -$8.6M | -$14.2M | -$16.5M | -$12.8M | -$12.4M | -$20.3M | -$23.6M | -$15.5M | -$11.2M | -$11.2M | |
| Capital Expenditure | -$76.1K | -$34.3K | -$212.3K | -$95.3K | -$34.2K | -$239.2K | -$67.7K | -$3.0K | $4.96 | -$3.0K | -$3.0K | |
| Free Cash Flow | -$3.8M | -$8.6M | -$14.4M | -$16.6M | -$12.8M | -$12.6M | -$20.4M | -$23.6M | -$15.5M | -$11.2M | -$11.2M | |
| Investing Cash Flow | $77.9K | -$34.3K | -$212.3K | -$95.3K | $102.7K | -$45.2M | $19.5M | $15.8M | $2.3M | $5.4M | $5.4M | |
| Financing Cash Flow | $6.1M | $5.3M | $20.6M | $26.7M | $299.1K | $61.1M | -$804.8K | $3.5M | $9.9M | $7.2M | $7.2M | |
| Issuance of Stock | $6.1M | $5.3M | $20.5M | $26.7M | $0.00 | $58.7M | $408.4K | $3.5M | $9.9M | $7.2M | $7.2M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $16.9K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $87.0K | |
| Net Change in Cash | $2.4M | -$3.1M | $6.1M | $10.1M | -$12.2M | $55.8M | -$47.6M | -$4.2M | -$3.2M | $1.4M | $2.0M |
Dilution Tracker
Shares outstanding grew 27407.3% over 5 years — significant dilution
Shares Outstanding
7M
5-Year Share Growth
+27407.3%
Stock Issuance (TTM)
$7.2M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.07 | 0.01 | 0.16 | 0.43 | 0.02 | 2.59 | 2.84 | 2.94 | 0.20 | 6.38 | 8.00 | |
| Change vs Prior % | — | -83.4% | 1299.9% | 172.6% | -94.6% | 11085.0% | 9.7% | 3.3% | -93.1% | 3043.3% | 25.5% | |
| Stock Issuance | $6.1M | $5.3M | $20.5M | $26.7M | $0.00 | $58.7M | $408.4K | $3.5M | $9.9M | $7.2M | $7.2M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $87.0K |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE % | -143.7% | 1610.2% | -140.7% | -219.9% | -108.2% | -20.3% | -76.3% | -142.5% | -103.0% | -72.9% | -70.8% | |
| ROA % | -83.8% | -469.9% | -108.1% | -137.7% | -93.7% | -19.4% | -64.2% | -109.3% | -82.2% | -65.1% | -74.3% | |
| ROIC % | -140.7% | 1542.2% | -130.2% | -121.7% | -96.8% | -20.0% | -76.8% | -146.4% | -106.3% | -77.6% | -91.7% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | -54.8% | -25.5% | -29.0% | -328.7% | 71.4% | 57.8% | -69.8% | -15.7% | 100.0% | 0.0% | |
| Operating Income | 35.0% | -102.7% | -38.8% | -50.4% | 43.7% | -12.1% | -130.6% | 10.8% | 42.1% | 35.1% | |
| Net Income | 36.9% | -107.2% | -40.7% | -97.2% | 57.0% | -6.8% | -121.4% | 12.4% | 42.4% | 35.5% | |
| EPS (Diluted) | 47.6% | -1169.5% | 90.1% | 27.4% | -697.8% | 99.0% | -101.7% | 15.0% | -736.5% | 97.9% | |
| Operating Cash Flow | 49.4% | -129.7% | -65.2% | -16.5% | 22.5% | 3.3% | -63.9% | -16.1% | 34.4% | 27.4% | |
| Free Cash Flow | 49.0% | -126.0% | -67.0% | -15.4% | 22.7% | 1.7% | -61.3% | -15.7% | 34.4% | 27.4% | |
| R&D Expense | -60.8% | 166.1% | 20.6% | 77.6% | -71.5% | 65.5% | 169.3% | 8.3% | -38.4% | -48.5% | |
| SG&A Expense | 97.3% | 38.2% | 75.3% | 9.7% | 19.5% | -15.6% | 91.4% | -38.8% | -51.8% | 9.4% | |
| Total Assets | 60.7% | -63.1% | 511.5% | 54.8% | -36.8% | 415.8% | -33.1% | -48.6% | -23.4% | -18.6% | |
| Book Value / Share | 28.7% | -211.3% | 215.0% | -44.2% | 1245.4% | -94.9% | -46.3% | -54.6% | 1053.0% | -97.1% | |
| Debt | 0.0% | 0.0% | 0.0% | 0.0% | 3.6% | -43.5% | -37.6% | 83.2% | -17.3% | -100.0% | |
| Diluted Shares | 19.3% | -83.4% | 1299.9% | 172.6% | -94.6% | 11084.6% | 9.7% | 3.3% | -93.1% | 3043.3% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B1.22
10Y Low / Med / High0.11 / 1.01 / 14.26
EV/EBITDAAt Loss
10Y Low / Med / High0.11 / 0.29 / 0.78
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$1.56
Tangible Book / Share
$1.09
Net Current Assets / Share
$1.24
Graham Net-Net
$0.95
Cash / Share
$0.84
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -10.02 | -0.79 | -7.94 | -1.42 | -0.22 | -5.75 | -1.32 | -0.25 | -0.11 | -1.16 | -1.29 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | 14.26 | -12.80 | 11.13 | 3.12 | 0.24 | 1.16 | 1.01 | 0.35 | 0.11 | 0.85 | 1.22 | |
| EV/EBITDA | -9.27 | -0.67 | -7.61 | -0.80 | 0.78 | -4.60 | -0.81 | 0.11 | 0.29 | -0.31 | -0.37 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-13.94
Distress
Piotroski F-Score
0
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $24.4M | $36.2M | $0.00 |
| Net Income | -$127.6K | -$191.3K | -$255.1K |
| EPS | $-0.02 | $-0.03 | $-0.04 |
| # Analysts (EPS) | 1 | 1 | 1 |